NewsInformation about ongoing discussions and negotiations concerning out-licensing of Xbrane Biopharma AB’s (Publ) products

Press release

In accordance with what has previously been communicated in press releases, interim reports and presentations, Xbrane is in discussions and negotiations with potential partners regarding out-licensing of our Spherotide and Xlucane products.

Negotiation concerning out-licensing of Spherotide in China is proceeding in the right direction and under the same terms as previously communicated. Our ambition is to sign a final agreement this year. Discussions and negotiations regarding out-licensing of Xlucane globally and Spherotide, especially in Europe, are ongoing. Overall commercial terms are agreed upon with a couple of potential partners who are currently undergoing an active evaluation of the products. No decisions have been taken nor agreements have been signed and if/when this happens, Xbrane will communicate such information to the market in accordance with current rules and regulations.

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777

Susanna Helgesen
CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636

This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.30 August 22, 2017.